IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1309-1316

  Mangia, Alessandra ^a   Santoro, Rosanna ^a   Sarli, Roberto ^b   Mottola, Leonardo ^a   Piazzolla, Valeria ^a   Petruzzellis, Daniela ^a   Bacca, Donato ^c   Clemente, Rocco ^d   Copetti, Massimiliano ^a   Di Mauro, Lazzaro ^a   Lotti, Giuseppe ^a   Sacco, Michele ^a   Stefano, Ippazio ^e  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b Thalassemic Diseases Center   (Italy)

^c Hospital Casarano   (Italy)

^d Hospital 'Madonna Delle Grazie' Matera   (Italy)

^e APLETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE; VIRUS ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN LEUKOCYTE ANTIGEN CLASS II GENE; INFECTION RISK; INTERLEUKIN 28B GENE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THALASSEMIA MAJOR; VIRAL CLEARANCE; VIRUS RESISTANCE;

ADULT; ALLELES; BETA-THALASSEMIA; BLOOD TRANSFUSION; COHORT STUDIES; DISEASE RESISTANCE; FEMALE; GENE FREQUENCY; GENOTYPE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HLA-DQ BETA-CHAINS; HUMANS; IMMUNITY, INNATE; INTERLEUKINS; ITALY; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, VIRAL; VIRAL LOAD;

EID: 83455179378     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1913     Document Type: Article

References (27)

1. Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board. J Viral Hepat 1999; 6:35-47.
2. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-1457.
3. Dintsios CM, Haverkamp A, Wiegand J, et al. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. Eur J Gastroenterol Hepatol 2010; 22:278-288.
4. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA 2000; 284:450-456. (Pubitemid 30484478)
5. Grebely J, Raffa JD, Lai C, et al. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007; 21:447-451. (Pubitemid 47307717)
6. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-88. (Pubitemid 36799109)
7. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004; 5:237-245. (Pubitemid 38967177)
8. Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354:2119-2124. (Pubitemid 30008896)
9. Donaldson PT. The interrelationship between hepatitis C virus and HLA. Eur J Clin Invest 1999; 29:280-283. (Pubitemid 29188820)
10. Asselah T, Bièche I, Paradis V, et al. Genetics, genomics and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007; 27:13-27.
11. Alric L, Fort M, Izopet J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113:1675-8.
12. Tibbs C, Donaldson P, Underhill J, et al. Evidence that the HLA DQA1*03 alleles confers protection from chronic HCV infection in Northen European Caucasoids. Hepatology 1996; 24:1342-1345. (Pubitemid 26399027)
13. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
14. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
15. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
16. Mangia A, Thompson AJ, Santoro R, et al. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 and 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139:821-827.e1.
17. Mangia A, Gentile R, Cascavilla I, et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999; 30:984-989. (Pubitemid 29278740)
18. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011; 106:38-45.
19. Hong X, Yu RB, Sun NX, et al. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2005; 11:7302-7307. (Pubitemid 43137680)
20. Wiese M, Grüngreiff K, Güthoff W, et al. Outcome in hepatitis C (genotype 1b) single source outbreak in Germany a 25-year multicenter study. J Hepatol 2005; 43:590-598. (Pubitemid 41253225)
21. Thio CL. Host genetic factors and antiviral immune responses to HCV. Clin Liver Dis 2008; 12:713-726. (Pubitemid 351952476)
22. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139:1586-1592.e1.
23. Bakr I, Rekacewicz C, El Hosseiny M, et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006; 55:1183-1187. (Pubitemid 44085688)
24. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome wide association study. Gastroenterology 2010; 138:1338-1345.e7.
25. Congia M, Clemente MG, Dessi C, et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996; 24:1338-1341. (Pubitemid 26399026)
26. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6:578-582. (Pubitemid 30305910)
27. Mangia A, Cascavilla I, Lezzi G, et al. HCV genotypes in patients with liver disease of different stage of severity. J Hepatol 1997; 26:1173-1178. (Pubitemid 27346627)